Search Results

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.

Equillium, Inc. announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

Equillium, Inc. today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.

Equillium, Inc. today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.

Equillium, Inc. today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.

Equillium, Inc. today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-month option exercise period to acquire Equillium’s rights to itolizumab.